Almost every GLP-1 provider prices one of two ways: the same amount every month whatever your dose, or more money as your dose goes up. That single structural choice can change your annual cost by several thousand dollars, and it is almost never the thing patients compare. This guide explains how each model works, does the arithmetic at real published prices, and shows which one suits which patient.

Quick Takeaway:

• Dose-tiered pricing rises as you titrate; flat-rate pricing does not change
• LillyDirect publishes Zepbound from $349 (2.5 mg) to $699 (10 mg) — roughly a doubling
• NovoCare® launched Wegovy at $499/month flat across all dose strengths
• Flat-price compounded providers advertise tirzepatide at $159–$163/month at any dose
• Because most patients titrate upward and stay there, flat pricing usually wins over a full year

Looking for a Better Alternative?

CoreAge Rx is our top-rated favorite for GLP-1 weight loss therapy, combining competitive pricing with exceptional customer service, faster medication delivery, and more comprehensive support resources.

Why we recommend CoreAge Rx:

• Lower monthly costs than most competitors ($179–$399 range)
• Faster prescription approval (typically 12–24 hours)
• More extensive provider support included at no extra charge
• Better medication availability during shortages
• Higher patient satisfaction scores (4.7/5)

New Patient Special: Save up to $200 on your first three months. Same-day prescription approval for qualifying patients. Rated 4.7/5 stars by verified customers. No insurance required.

The Two Models

Dose-tiered pricing charges by dose strength. The rationale is straightforward — a higher dose contains more active drug, so it costs more to supply. Most manufacturer channels and most UK providers work this way.

Flat-rate pricing charges the same regardless of dose. Providers using it are effectively averaging across their patient population: low-dose patients subsidise high-dose patients, and the provider gains simplicity and a marketing advantage.

Who Uses Which

The Arithmetic

Consider a patient who titrates tirzepatide over four months and then stays at 10 mg for the rest of the year — a completely standard trajectory.

Dose-tiered, via LillyDirect:

Flat-rate, via a compounded provider at $163:

The difference is $5,332 over a year. Some of that gap is the compounded-versus-approved distinction rather than the pricing model — but the structural point holds even comparing like with like.

Flat versus tiered, both FDA-approved:

That is $200 a month, or $2,400 a year, for a difference in average trial efficacy of a few percentage points. Whether that trade is worth making is a clinical conversation — but you cannot have it if you have not noticed the pricing structures differ.

Important: The comparison only works if you model your maintenance dose. At 2.5 mg, LillyDirect's $349 beats NovoCare's $499. At 10 mg, it loses by $200. Which provider is cheaper genuinely depends on where you end up, and most patients end up higher than they expect.

When Tiered Pricing Wins

Flat pricing is not universally better.

• You respond well at a low dose. Plenty of patients get good results at 2.5 mg or 5 mg tirzepatide and never need to escalate. At those doses, tiered channels are cheaper.
• You are microdosing deliberately. If your clinician is keeping you below the standard ladder, you are paying flat-rate prices for drug you are not using. See our microdosing guide.
• You are in a maintenance phase after reaching your goal. Some patients reduce dose to maintain, which tiered pricing rewards.
• You are only trialling treatment. If you may stop after two months at a starter dose, tiered pricing limits your exposure.

The Hidden Variants

Two structures sit between the models and catch people out.

Same-dose multi-month plans. Coby Health publishes six-month plans priced by the dose you lock in — $179/mo at 2.5 mg through $279/mo at 7.5 mg. The saving is real, but if your clinician escalates you at week eight you are renegotiating rather than titrating. Ask how mid-plan escalation is handled before prepaying.

Refill-timing rules. LillyDirect's 7.5 mg strength is $499 on initial fill and refills within 45 days, but $599 for refills after 45 days. That is a $100 monthly penalty for a calendar error, not a dose change.

How to Compare Properly

1. Estimate your maintenance dose. Ask your prescriber what dose they expect you to reach. Most tirzepatide patients titrate to 7.5 mg or above.
2. Price twelve months, not one. Build the table above for your own trajectory.
3. Add every recurring fee. Membership fees on top of medication change the ranking entirely — see our provider cost comparison.
4. Check the refill rules. Timing penalties are real money.
5. Then compare product type. Compounded versus FDA-approved is a separate decision from pricing structure, and should be made on its own terms.

Frequently Asked Questions

What is flat-rate GLP-1 pricing?

A pricing model where the monthly cost is the same regardless of your prescribed dose. Providers including Refills and Gimme Care advertise flat pricing, and NovoCare® launched Wegovy at $499 per month for all dose strengths.

Which is cheaper, flat or dose-tiered pricing?

It depends on your maintenance dose. At low doses, tiered channels are usually cheaper — LillyDirect's $349 at 2.5 mg beats NovoCare's $499 flat. At high doses, flat pricing wins: $499 flat beats $699 at 10 mg. Because most patients titrate upward and stay there, flat pricing usually wins over a full year.

Why do some providers charge more for higher doses?

Higher doses contain more active drug, so they cost more to supply. Manufacturer channels and most UK providers price this way. Flat-rate providers average across their patient population instead.

Does flat pricing mean lower quality medication?

Not inherently — pricing structure and product type are separate questions. Most flat-price providers in the US dispense compounded preparations, which are not FDA-approved, but NovoCare® uses flat pricing for FDA-approved Wegovy. Judge the product and the pricing model separately.

What is a same-dose multi-month plan?

A plan that prices a fixed number of months at a fixed dose. It offers real savings but constrains titration — if your clinician wants to escalate mid-plan, terms may need renegotiating. Ask before prepaying.

What is LillyDirect's 45-day refill rule?

LillyDirect publishes Zepbound 7.5 mg at $499 for the initial fill and refills within 45 days, and $599 for refills after 45 days. Letting a refill lapse past that window costs $100 a month at the same dose.

Bottom Line

Pricing structure is the most consequential variable most patients never compare. Over a year at a maintenance dose, the difference between flat and tiered pricing routinely exceeds $2,000 — and can exceed $5,000 when compounded and manufacturer channels are compared.

Ask your prescriber what maintenance dose they expect you to reach, then price twelve months at that dose across both models. If you expect to titrate high, flat pricing is worth actively seeking out. If you respond at a low dose or are only trialling treatment, tiered pricing limits your exposure.

CoreAge Rx: one all-in monthly price from $179–$399 including medication, provider messaging, and titration support — with dose managed clinically rather than priced as an upsell. Save up to $200 on your first three months.

Medical disclaimer: Informational only, not medical or financial advice. GLP-1 receptor agonists are prescription medicines with real risks and contraindications. Never choose or change a dose for pricing reasons without your prescriber's direction. Pricing changes frequently and should be verified directly.

Sources: LillyDirect and NovoCare® published self-pay pricing; provider published pricing pages as cited in the linked reviews; independent GLP-1 provider price trackers.

Date reviewed: August 2026